Agios Announces FDA Approval of PYRUKYND® (mitapivat) a

– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status...

Related Keywords

Boston , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , American , Kim Hall , Jackie Fouse , Company To Provide Robust Patient Access Programs , Cancer Center , European Hematology Association , Drug Administration , Harvard Medical School , Patient Assistance Program , Nasdaq , American Society Of Hematology , European Medicines Agency , Agios Pharmaceuticals Inc , Virtual Congress , Approval Based , Supports Treatment , Transfusion Status , Provide Robust Patient Access Programs , Free Medication , Eligible Patients , Host Investor Webcast Tomorrow , Hanny Al Samkari , Mass General Cancer Center , Rachael Grace , Boston Children , Priority Review , Hematology Association , Annual Meeting , Nasdaq Agio , Agios Pharmaceuticals , Nc ,